Lilly buys three companies in one day to build an infectious disease business

Eli Lilly announced on May 26, 2026, that it would acquire three companies in one day to build a new infectious disease business: Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc. ^[1] The deals could be worth up to $3.83 billion combined, though the final amounts depend on whether the companies hit certain clinical, regulatory, or commercial milestones ^[1].

The largest deal, worth up to $1.55 billion, is for Vaccine Company, which is developing a nanoparticle vaccine technology. Its lead candidate targets Epstein-Barr virus, a common infection linked to multiple sclerosis and some cancers ^[1]. Curevo could bring in up to $1.5 billion for its shingles vaccine candidate, amezosvatein, which in a Phase 2 trial matched the immune response of the current standard shingles vaccine while cutting side effects like fatigue, chills, and injection-site pain by more than half ^[1]. LimmaTech Biologics, valued at up to $780 million, is working on vaccines against drug-resistant bacteria, including Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis ^[1]. Its lead program, LTB-SA7, is a Phase 1 vaccine against S. aureus, a leading cause of surgical-site infections ^[1].

Lilly executive Daniel M. Skovronsky said the strategy is meant to "prevent disease at its source rather than treat its consequences," citing evidence linking common infections to conditions like neurological disease, cancer, and infertility that can show up years after the initial illness ^[1]. The company also pointed to rising antimicrobial resistance as a reason vaccines are becoming the only realistic way to prevent some bacterial infections ^[1].

All three deals still need to close, and they are subject to standard conditions including the waiting period under federal antitrust law ^[1]. None of the vaccine candidates involved have been approved by any regulatory authority, and Lilly's own press release cautions that there is no guarantee the acquisitions will close or that the products will ever reach the market ^[1].

Why it matters for patients

This news does not change anything about current GLP-1 medications like Ozempic, Wegovy, Mounjaro, or Zepbound. None of the three companies Lilly is buying work on obesity or diabetes drugs. But the move shows Lilly using some of the revenue and momentum from its incretin business to expand into an entirely new area: vaccines aimed at preventing infections tied to long-term diseases.

For people who already take Lilly's obesity or diabetes drugs, the practical takeaway is limited for now. The shingles, bacterial, and Epstein-Barr virus vaccine candidates are all still in early or mid-stage development, and it is not yet known when or whether any of them will reach pharmacy shelves. The shingles vaccine candidate has only completed a Phase 2 trial, the S. aureus vaccine is in Phase 1, and the Epstein-Barr virus candidate is described as "Phase 1-ready," meaning it has not yet started human testing ^[1].

What this signals is a broader business shift at Lilly, a company already known to patients for tirzepatide products. Whether that shift affects pricing, research funding, or availability of Lilly's existing diabetes and obesity medicines is not addressed in the announcement and is not yet known.

What happens next

The deals require regulatory clearance, including expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ^[1]. Lilly says it will determine how to account for the acquisitions under standard accounting rules once they close, and will reflect the deals in future financial results and guidance ^[1]. No specific closing date was given in the announcement, and no timeline was provided for when any of the three vaccine candidates might file for regulatory approval.